Imatinib Teva

Imatinib, the active ingredient in Imatinib Teva, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib Teva is a targeted antineoplastic agent that interferes with specific oncogenic signaling pathways.

- Chronic myeloid leukemia (CML): helps achieve hematologic and cytogenetic remission by suppressing malignant clone proliferation. - Gastrointestinal stromal tumor (GIST): reduces tumor growth and disease progression in patients with KIT or PDGFRA mutations. - Philadelphia‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission when used in combination regimens.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Fatigue: generalized tiredness. - Diarrhea: loose stools. - Muscle cramps: occasional skeletal discomfort. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Myelosuppression: neutropenia, anemia, or thrombocytopenia. - Cardiotoxicity: congestive heart failure signs. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Pulmonary hypertension: shortness of breath and elevated pulmonary pressure. - Renal impairment: increased creatinine or reduced clearance.

Patients and prescribers should consider several safety measures before and during therapy.

- Baseline assessment: obtain complete blood count, liver function tests, and renal function before initiating treatment. - Monitoring: perform regular hematologic and biochemical labs to detect early toxicity. - Drug interactions: review concomitant medications for potential CYP3A4 modulators. - Pregnancy and lactation: avoid use unless benefits clearly outweigh potential risks. - Cardiovascular health: assess cardiac function in patients with pre‑existing heart disease. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Imatinib may alter the pharmacokinetics of several co‑administered agents.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce imatinib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase plasma levels and toxicity risk.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors, antacids): may affect absorption, consider timing adjustments. - Anticoagulants (e.g., warfarin): monitor INR more frequently. - Vaccines: live attenuated vaccines should be avoided during therapy. - Concomitant chemotherapy: assess overlapping toxicities, especially myelosuppression.